agonist

(redirected from Partial agonist)
Also found in: Dictionary, Thesaurus, Medical.
Related to Partial agonist: therapeutic index, Inverse agonist

agonist

[′ag·ə‚nist]
(biochemistry)
A chemical substance that can combine with a cell receptor and cause a reaction or create an active site.
(physiology)
A contracting muscle that is resisted or counteracted by another muscle, called an antagonist, with which it is paired.
References in periodicals archive ?
Rapastinel (GLYX-13) is an investigational intravenous formulation of a novel NMDA receptor partial agonist, which is being evaluated for adjunctive treatment of MDD, and has shown a rapid onset of antidepressant efficacy 1 day after a single dose in a Phase 2 clinical trial of patients with MDD who had an inadequate response to one or more antidepressants.
The second class comprises the partial agonists (1 [micro]M [less than or equal to] [K.
Relevance of Vilazodone's 5-HT1A receptor partial agonist effect
Researchers have studied the effects of dopamine partial agonists (1)-agents that block the activities of the dopamine receptors (i.
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Moreover, efficacy of aripiprazole is mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
At lower concentrations, the difference between GCA and TEF approaches depended on the efficacy of the partial agonist.
Because it is a partial agonist, with increasing dose the effects plateau, making it safer and less likely to result in accidental overdose than full agonists.
D-cycloserine, a NMDA receptor partial agonist, is currently approved for other uses, but is expected to be used at a substantially lower dosage in the treatment of anxiety disorders.
Varenicline is pharmacologically known as an alpha4beta2 nicotinic acetylcholine receptor partial agonist, which means that it activates the brain's nicotinic receptors in a manner similar to nicotine, but with less affinity (effect).
There are two possible explanations for this finding: tamoxifen resistance might be overcome by a change in treatment; or aromatase inhibitors might simply be a better treatment option, since they reduce peripheral estrogen concentrations to extremely low levels, whereas tamoxifen is a partial agonist," wrote the investigators, who were led by Raimund Jakesz, M.
Food and Drug Administration (FDA) for cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.